8-K: REGENXBIO Faces FDA Clinical Hold on RGX-121 for MPS II

REGENXBIO announced an FDA clinical hold on its RGX-121 investigational gene therapy for MPS II due to asymptomatic spine MRI findings, with no near-term BLA resubmission expected.

Summary

• REGENXBIO received a clinical hold from the FDA for its investigational gene therapy RGX-121, intended for Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome.
• The hold was issued following the identification of asymptomatic spine MRI findings in five participants of the CAMPSIITE study.
• The company does not anticipate resubmitting the Biologics License Application (BLA) for RGX-121 in the near term.
• These findings are believed to be unique to the MPS II program and require further data analysis to assess the benefit-risk profile.
• REGENXBIO is prioritizing its Duchenne and retinal disease candidates, with planned BLA submission for the Duchenne candidate this quarter and topline pivotal data for wet AMD in Q4.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development due to the clinical hold on a key program and the uncertainty surrounding its resubmission.

Positives

• All five participants with MRI findings continue to be clinically well and show stability or improvement in neurocognitive and neurobehavioral assessments.
• Radiologists believe the identified spine MRI findings are likely benign.
• No brain nodules or masses were identified on any brain MRIs.
• REGENXBIO is focused on advancing its Duchenne and retinal disease candidates with near-term catalysts.
• RGX-121 has received Orphan Drug Product, Rare Pediatric Disease, Fast Track, and RMAT designations from the FDA, and ATMP classification from the EMA.

Negatives

• The FDA has placed a clinical hold on the investigational new drug application for RGX-121.
• Asymptomatic spine MRI findings were discovered in five participants in the CAMPSIITE study.
• REGENXBIO does not expect to resubmit the RGX-121 Biologics License Application (BLA) in the near term.
• The clinical hold necessitates longer-term follow-up and additional data analysis to assess the benefit-risk profile of RGX-121.
• The underlying prevalence and clinical significance of these asymptomatic findings in the MPS II patient population are unknown due to the lack of routine spine MRIs in clinical practice or trials for this condition.

Risks

• The clinical hold on RGX-121 introduces significant uncertainty regarding its development timeline and potential approval.
• The unknown prevalence and clinical significance of the asymptomatic spine MRI findings could pose challenges in demonstrating safety and efficacy.
• The need for longer-term follow-up and additional data analysis may delay future regulatory submissions and commercialization.
• The company's focus may be diverted from other promising pipeline candidates due to the complexities of addressing the clinical hold.
• Potential for unforeseen issues arising from the ongoing monitoring of the five affected participants.

Future Outlook

REGENXBIO expects to submit the Duchenne BLA this quarter and announce wet AMD pivotal data in the fourth quarter. The company is focused on these programs while addressing the RGX-121 clinical hold, with no near-term resubmission of the RGX-121 BLA anticipated.

Management Comments

• "We believe these findings are unique and limited to our Hunter Syndrome program, and require longer-term follow-up and additional data analysis to assess the benefit-risk profile of RGX-121," said Curran Simpson, President and CEO of REGENXBIO.
• "We remain focused on our Duchenne and retinal disease candidates, which utilize a different capsid and routes of administration, with near-term catalysts that are on track, including the planned submission of the Duchenne BLA this quarter and the wet AMD topline pivotal data announcement in the fourth quarter."
• "While imaging natural history is limited for this ultra-rare disease, I believe that asymptomatic, likely benign findings like these may be inherent to the impact of Hunter Syndrome throughout the body," said Roberto Giugliani, M.D., Ph.D.
• "I am pleased that these patients are doing well and remain asymptomatic."

Industry Context

StockSavvy.ai notes that clinical holds, especially for gene therapies targeting rare diseases, represent significant setbacks and can lead to substantial delays and increased development costs. The FDA's scrutiny on MRI findings highlights the importance of long-term safety monitoring in novel therapeutic areas. Competitors in the rare disease space often face similar regulatory hurdles, emphasizing the need for robust data and transparent communication with regulatory bodies.

Stakeholder Impact

• Shareholders may experience negative sentiment and a potential decrease in stock value due to the clinical hold and delayed BLA resubmission for RGX-121.
• Patients and families affected by MPS II face continued uncertainty regarding the availability of RGX-121 as a treatment option.
• The company's focus on addressing the RGX-121 issue may impact resource allocation for other pipeline programs, potentially affecting future growth prospects.

Next Steps

• Conduct longer-term follow-up and additional data analysis for RGX-121.
• Incorporate FDA feedback, including the full clinical hold letter, into next steps for RGX-121.
• Continue to observe patients with asymptomatic MRI findings with periodic imaging.
• Submit the Duchenne BLA this quarter.
• Announce wet AMD topline pivotal data in the fourth quarter.

Key Dates

Recommendation

The FDA clinical hold on RGX-121, a key program for REGENXBIO, coupled with the uncertainty of near-term BLA resubmission, presents a significant negative development. While other pipeline candidates offer some offset, the delay and associated risks for RGX-121 warrant a cautious approach, suggesting a sell recommendation until clarity on the hold resolution and future prospects emerges.

Keywords

RGX-121, MPS II, Hunter Syndrome, Clinical Hold, FDA, Gene Therapy, Biologics License Application, CAMPSIITE study